0001615219-16-000179.txt : 20160524 0001615219-16-000179.hdr.sgml : 20160524 20160524172041 ACCESSION NUMBER: 0001615219-16-000179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160523 FILED AS OF DATE: 20160524 DATE AS OF CHANGE: 20160524 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flex Pharma, Inc. CENTRAL INDEX KEY: 0001615219 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465087339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-874-1821 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Westphal Christoph H CENTRAL INDEX KEY: 0001291961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36812 FILM NUMBER: 161672730 MAIL ADDRESS: STREET 1: C/O ALNYLAM PHARMACEUTICALS, INC STREET 2: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 wf-form4_146412482886817.xml FORM 4 X0306 4 2016-05-23 0 0001615219 Flex Pharma, Inc. FLKS 0001291961 Westphal Christoph H C/O FLEX PHARMA, INC. 800 BOYLSTON STREET BOSTON MA 02199 1 1 1 0 President and CEO Common Stock 2016-05-23 4 P 0 13367 12.31 A 3090994 I See notes Common Stock 2016-05-24 4 P 0 16967 12.50 A 3107961 I See notes Common Stock 3925248 D The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $12.02 to $12.98. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. On May 23, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 13,367 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 393,730 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $12.05 to $12.79. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. On May 24, 2016, Longwood Fund III purchased 16,967 Common Shares. Following such purchase, Longwood Fund III owned 410,697 Common Shares and Longwood Fund II owned 2,697,264 Common Shares. /s/ Robert Hadfield, Attorney-in-Fact 2016-05-24